Clinical Trials

    Showing 1 - 10 of 10 Polly Niravath

    Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer (INTEGRAL)

    Status: Open Not Enrolling

    Investigator: Polly Niravath

    Study Coordinator: Milan Sheth

    Phone: 713.790.3311

    The purpose of this research study is to test the safety and effectiveness of docetaxel chemotherapy and pembrolizumab plus adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy in patients with anthracycline-refractory, triple negative breast ... Read more >

    A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative

    Status: Open Not Enrolling

    Investigator: Polly Niravath

    Study Coordinator: Alexys Brock

    Phone: 346.238.4814

    This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whe... Read more >

    A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ? 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

    Status: Open Not Enrolling

    Investigator: Polly Niravath

    Study Coordinator: Alexys Brock

    Phone: 346.238.4814

    This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.... Read more >

    Acupuncture Trial

    Status: Open Not Enrolling

    Investigator: Polly Niravath

    Study Coordinator: Milan Sheth

    Phone: 713.790.3311

    A single arm pilot study of 20 patients will be used to determine the feasibility of EA as a treatment for cancer survivors who have been treated with curative intent, but who have persistent CIPN for ?3 months after the cancer treatment is completed... Read more >

    Fulvestrant Plus Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

    Status: Enrolling

    Investigator: Polly Niravath

    Study Coordinator: Alexys Brock

    Phone: 346.238.4814

    The study will investigate if a one month drug holiday from the CDK4/6 inhibitor drug, abemaciclib, will restore the body's sensitivity to the drug and make the subsequent treatment of abemaciclib plus fulvestrant more effective.... Read more >

    Multicenter Phase I/Ib Trial of Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

    Status: Open Not Enrolling

    Investigator: Polly Niravath

    Study Coordinator: Alexys Brock

    Phone: 346.238.4814

    This is a Phase I/Ib study testing the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer. Cancer cells grow in an uncontrolled manner and this causes... Read more >

    Multicenter Phase II Trial of Durvalumab (MEDI4736) With Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)

    Status: Open Not Enrolling

    Investigator: Polly Niravath

    Study Coordinator: Milan Sheth

    Phone: 713.790.3311

    The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.... Read more >

    PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2

    Status: Open Not Enrolling

    Investigator: Polly Niravath

    Study Coordinator: Milan Sheth

    Phone: 713.790.3311

    This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). Th... Read more >

    REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

    Status: Open Not Enrolling

    Investigator: Polly Niravath

    Study Coordinator: Alexys Brock

    Phone: 346.238.4814

    This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens.... Read more >

    SWOG 1007

    Status: Open Not Enrolling

    Investigator: Polly Niravath

    Study Coordinator: Milan Sheth

    Phone: 713.790.3311

    RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestan... Read more >